{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+1&page=3",
    "query": {
      "intervention": "Combination Agent 1",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 4092,
    "total_pages": 410,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+1&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+1&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T19:35:13.390Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06471673",
      "title": "A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Tumor",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Malignant Tumor of Breast",
        "Tumors, Breast"
      ],
      "interventions": [
        {
          "name": "BC1 cell line",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bria-OTS regimen and CPI (tislelizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bria-OTS regimen and CPI (tislelizumab) expansion cohort",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BriaCell Therapeutics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-05-29",
      "completion_date": "2025-10-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-26",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06471673"
    },
    {
      "nct_id": "NCT07123454",
      "title": "A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AZD4512",
          "type": "DRUG"
        },
        {
          "name": "Surovatamig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2025-09-24",
      "completion_date": "2029-02-15",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 8,
      "location_summary": "Irvine, California • Jacksonville, Florida • Rochester, Minnesota + 4 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07123454"
    },
    {
      "nct_id": "NCT02658396",
      "title": "GO-203-2C + Bortezomib For Relapsed Or Refractory MM",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Multiple Myeloma in Relapse",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "GO-203-2C",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": "2022-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-05",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658396"
    },
    {
      "nct_id": "NCT05394103",
      "title": "Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "Mocaciclib (Q901)",
          "type": "DRUG"
        },
        {
          "name": "KEYTRUDA® (pembrolizumab)",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qurient Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-08-30",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05394103"
    },
    {
      "nct_id": "NCT02040142",
      "title": "HIPEC for Peritoneal Carcinomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peritoneal Carcinomatosis",
        "Colorectal Cancer",
        "Appendiceal Cancer",
        "Peritoneal Mesothelioma",
        "Pseudomyxoma Peritonei",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "HIPEC",
          "type": "PROCEDURE"
        },
        {
          "name": "Mitomycin C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2011-11",
      "completion_date": "2024-08-19",
      "has_results": true,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02040142"
    },
    {
      "nct_id": "NCT02605954",
      "title": "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC",
          "type": "DRUG"
        },
        {
          "name": "Third Antiretroviral Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2015-11-18",
      "completion_date": "2018-01-24",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605954"
    },
    {
      "nct_id": "NCT01308580",
      "title": "Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel (XRP6258)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone (or Prednisolone)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1200,
      "start_date": "2011-04",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 21,
      "location_summary": "Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01308580"
    },
    {
      "nct_id": "NCT03950570",
      "title": "ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abraxane",
          "type": "DRUG"
        },
        {
          "name": "ORIN1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orinove, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2019-05-25",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2024-12-31",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 20,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • Burbank, California + 16 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03950570"
    },
    {
      "nct_id": "NCT00811954",
      "title": "Comparative Study of Three NNRTI-Sparing HAART Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Emtricitabine/tenofovir disoproxil fumarate",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1814,
      "start_date": "2009-05",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-09-05",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811954"
    },
    {
      "nct_id": "NCT00001122",
      "title": "A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 74,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-02",
      "last_synced_at": "2026-11-13T19:35:13.390Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Dallas, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001122"
    }
  ]
}